Epygen Biotech private limited is a Biotechnology organization promoted by the founders of of Epygen Labs in OUNDERS OF Epygen Labs headquartered in Dubiotech park, Dubai, UAE with offices, labs and manufacturing facilities in Dubai, India and USA.
Epygen’s current focus area is in Biopharmaceuticals, to produce Biosimilar Therapeutic Protein rSK for the cardiovascular segment. It also plans to utilize its skills in E .coli based expression and protein purification to produce other therapeutic proteins in future filling up its pipelines. Epygen endeavours to utilize the decade old experience of its promoters and biotechnologists in USA and India to license in E.coli and animal based technologies for producing Biosimilar Oncology drugs in future, targeting a US $ 70 billion Global Biosimilar opportunity.
Epygen Biotech Private Limited exhibits unique capabilities in the Enzyme Biotechnology field. To fully utilize its potential in fermentation and protein expression, Epygen has tied up with CSIR-IMTECH, for scaling up its recombinant Streptokinase technology for large-scale production of this critical therapeutic protein at an affordable cost. Through this Licensing and technology transfer agreement with CSIR-IMTECH, Epygen aims to take this life-saving cardiovascular Thrombolytic drug to patients in Indian subcontinent and the underprivileged of the world, at an affordable cost but abiding highest quality standards.
Name and contact details of Chairperson/Managing director
• Recombinant Streptokinase,
• High cell density fermentation,
• IB isolation and Refolding scale-up,
• Protein Purification,
• Stress resistant enzyme development.
14, Raheja Arcade, G. Floor, Sector 11, CBD Belapur, Navi Mumbai 400614